Rezpegaldesleukin is an experimental drug that modulates interleukin-2 and is in development for psoriasis, atopic dermatitis, and alopecia areata. From Wikipedia
The FDA granted Fast Track status in February after strong midstage data highlighted its potential to address unmet needs in moderate-to-severe atopic dermatitis.
